Type I Diabetes (T1D) Drug Development

Creative Biolabs is a leading service provider that focuses on drug development. Our scientists are always dedicated to assisting our clients with the most satisfactory drug development services for type I diabetes based on our integrated platform and professional science teams.

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by insulin deficiency due to T cell-mediated destruction of β-cells and leads to hyperglycemia. Although T1D can be diagnosed at any age, it is one of the most common chronic diseases occurring in childhood. The complications consist of microvascular and macrovascular diseases, which account for the significant morbidity and mortality associated with T1D. The pathophysiological basis of these complications remains uncertain, but hyperglycemia appears to play a central role. Although T1D accounts for only 5-10% of all cases of diabetes, it remains a severe chronic disorder with serious short-term and long-term implications.

Treatment of T1D

Ever since the discovery of insulin, patients with T1D have relied on multiple daily insulin injections to survive an otherwise deadly disease. However, despite decades of research and clinical trials, no means for preventing or treatment yet exists to stop the autoimmune destruction of β cells.

Pathogenesis of T1D. Fig.1 Pathogenesis of T1D. (Katsarou, 2017)

The last decade has seen extraordinary progress in our understanding and treatment of T1D. The T-cell-mediated autoimmune origin of T1D has prompted efforts to prevent the progression of the disease by targeting T lymphocytes. When studied in patients with T1D, several immune suppression have been reported to delay the decline in β-cell function and slow insulin production loss. Promising therapy types include single-compound trials with monoclonal anti-CD3 antibodies and anti-CD20 antibodies.

Short treatments with anti-CD3 antibodies could delay clinical T1D in high-risk participants and reduce the loss of β-cell function. Combination therapies that target several pathogenic pathways and improve β-cell viability might be needed to preserve endogenous insulin production in patients with T1D. Furthermore, the use of islet-cell transplantation and stem cells as insulin-producing surrogates for β cells remains hopeful in combination with an immunoprotective barrier to provide a therapeutically meaningful advance.

Custom Services for T1D Drug Development

The increased understanding of the pathogenesis of the disease and the identification of factors that control disease incidence have provided a wealth of potential targets for disease intervention to revolutionize therapy of T1D. Creative Biolabs is your dependable service provider combining our state-of-the-art platforms with the knowledge and experience of our experts. We provide a full range of drug development services, including but not limited to:

  • Monoclonal Antibody Development for T1D
  • Bispecific Antibody Development for T1D
  • Cell-based Therapy for T1D

At Creative Biolabs, our mission is to provide individual support, quick response times, technical expertise combined with the highest quality standards. Depending on your current phase of development, we can adapt our drug development capacities to your needs. If you are interested in our services, please feel free to contact us for more detailed information.


  1. Katsarou, A.; et al. Type 1 diabetes mellitus. Nature reviews Disease primers. 2017, 3(1): 1-17.

For Research Use Only | Not For Clinical Use

Online Inquiry

Autoimmune Diseases

We are dedicated to advancing and facilitating your drug development against autoimmune diseases Contact us USA
  • Location:
  • Call:
  • Fax:
  • Email:
  • Location:
  • Call:
  • Email:
  • Location:
  • Call:
  • Email:

Autoimmune Diseases,Drug Development for
Autoimmune Diseases

Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.

Copyright © 2024 Creative Biolabs. All Rights Reserved.